JP2008529497A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008529497A5 JP2008529497A5 JP2007554287A JP2007554287A JP2008529497A5 JP 2008529497 A5 JP2008529497 A5 JP 2008529497A5 JP 2007554287 A JP2007554287 A JP 2007554287A JP 2007554287 A JP2007554287 A JP 2007554287A JP 2008529497 A5 JP2008529497 A5 JP 2008529497A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- isolated antibody
- epha2
- antigen
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 34
- 102000051096 EphA2 Receptor Human genes 0.000 claims 26
- 108010055196 EphA2 Receptor Proteins 0.000 claims 26
- 239000012634 fragment Substances 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 101150042817 NFS1 gene Proteins 0.000 claims 8
- 101100126298 Rickettsia conorii (strain ATCC VR-613 / Malish 7) iscS gene Proteins 0.000 claims 8
- 101150114492 SPL1 gene Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65004705P | 2005-02-04 | 2005-02-04 | |
| US60/650,047 | 2005-02-04 | ||
| PCT/US2006/004057 WO2006084226A2 (en) | 2005-02-04 | 2006-02-06 | Antibodies that bind to epha2 and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008529497A JP2008529497A (ja) | 2008-08-07 |
| JP2008529497A5 true JP2008529497A5 (enExample) | 2009-04-02 |
| JP5342145B2 JP5342145B2 (ja) | 2013-11-13 |
Family
ID=36778009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554287A Expired - Fee Related JP5342145B2 (ja) | 2005-02-04 | 2006-02-06 | ＥｐｈＡ２に結合する抗体およびその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7569672B2 (enExample) |
| EP (1) | EP1846450B1 (enExample) |
| JP (1) | JP5342145B2 (enExample) |
| KR (1) | KR101363252B1 (enExample) |
| CN (2) | CN104059150B (enExample) |
| AT (1) | ATE551367T1 (enExample) |
| AU (1) | AU2006210460B2 (enExample) |
| BR (1) | BRPI0607450A2 (enExample) |
| CA (1) | CA2597198C (enExample) |
| CR (1) | CR9332A (enExample) |
| IL (1) | IL184803A (enExample) |
| MX (1) | MX2007009403A (enExample) |
| NO (1) | NO20074474L (enExample) |
| RU (1) | RU2007133108A (enExample) |
| WO (1) | WO2006084226A2 (enExample) |
| ZA (1) | ZA200707275B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192698B1 (en) * | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
| US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| WO2006084226A2 (en) * | 2005-02-04 | 2006-08-10 | Raven Biotechnologies, Inc. | Antibodies that bind to epha2 and methods of use thereof |
| KR20080080482A (ko) * | 2005-09-07 | 2008-09-04 | 메디뮨 엘엘씨 | 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체 |
| EA020324B1 (ru) * | 2006-07-18 | 2014-10-30 | Санофи-Авентис | АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ |
| KR101523698B1 (ko) | 2007-01-22 | 2015-05-29 | 마크로제닉스 웨스트 인코퍼레이티드 | 사람 암 줄기세포 |
| JP2010530437A (ja) * | 2007-06-18 | 2010-09-09 | メディミューン，エルエルシー | ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療 |
| WO2009151717A2 (en) | 2008-04-02 | 2009-12-17 | Macrogenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
| DK2199390T3 (en) * | 2007-08-30 | 2017-04-03 | Daiichi Sankyo Co Ltd | ANTI-EphA2 ANTIBODY |
| US20110281279A1 (en) * | 2007-12-21 | 2011-11-17 | Siemens Healthcare Diagnostics Inc. | CIRCULATING Epha2 RECEPTOR |
| JP5117917B2 (ja) | 2008-04-21 | 2013-01-16 | デクセリアルズ株式会社 | 保護素子及びその製造方法 |
| US8715654B2 (en) | 2008-10-02 | 2014-05-06 | Celtaxsys, Inc. | Methods of modulating the negative chemotaxis of immune cells |
| EP3482769B1 (en) | 2008-12-19 | 2024-05-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| EP2498797A4 (en) * | 2009-11-09 | 2013-12-25 | Brigham & Womens Hospital | TREATMENT OF CARDIOPATHY |
| WO2011057249A2 (en) | 2009-11-09 | 2011-05-12 | The Brigham And Women's Hospital, Inc. | Treatment of heart disease |
| SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2012012759A2 (en) | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anti-tumor antigen antibodies and methods of use |
| CN103154025B (zh) | 2010-08-02 | 2015-07-01 | 宏观基因有限公司 | 共价双抗体及其用途 |
| JP6145088B2 (ja) | 2011-05-21 | 2017-06-07 | マクロジェニクス，インコーポレーテッド | 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用 |
| EP2748197A2 (en) | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| CA2850668A1 (en) * | 2011-10-04 | 2013-04-11 | Expression Pathology, Inc. | Srm/mrm assay for the ephrin type-a receptor 2 protein |
| JP5875054B2 (ja) * | 2013-02-13 | 2016-03-02 | 国立大学法人 東京大学 | がんの検査方法及び検査用キット |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| US9458245B2 (en) | 2013-03-06 | 2016-10-04 | Merrimack Pharmaceuticals, Inc. | ANTI-C-MET tandem Fc bispecific antibodies |
| SG10201913324PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| KR101636882B1 (ko) * | 2015-06-25 | 2016-07-06 | 전남대학교 산학협력단 | 인간 피브로넥틴 도메인 Ⅲ 기본 골격의 신규 인간 ＥｐｈＡ2 특이적 결합 단백질 및 그의 용도 |
| SI3328419T1 (sl) | 2015-07-30 | 2021-11-30 | Macrogenics, Inc. | PD-1-vezavne molekule in postopki uporabe le-teh |
| AU2016370376B2 (en) | 2015-12-14 | 2023-12-14 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
| EP3572426A4 (en) * | 2017-01-23 | 2020-12-23 | Toyo University | ANTI-BODY ANTI-EPHA2 AND IMMUNOLOGICAL DETECTION OF EPHA2 CALLING ANTI-BODY AUDIT |
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| AU2019222666B2 (en) | 2018-02-15 | 2025-12-04 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
| JP7326764B2 (ja) * | 2018-03-09 | 2023-08-16 | 東ソー株式会社 | 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法 |
| CN115279403A (zh) | 2020-02-21 | 2022-11-01 | 宏观基因有限公司 | Cd137结合分子及其用途 |
| IL298868A (en) * | 2020-06-12 | 2023-02-01 | Bicycletx Ltd | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) |
| CN117693519A (zh) | 2021-05-25 | 2024-03-12 | 瓦克斯细胞生物 | 基于单体拟抗体的嵌合抗原受体和包含其的免疫细胞 |
| KR20230140746A (ko) * | 2022-03-30 | 2023-10-10 | 연세대학교 산학협력단 | 암전이의 검출용 신규 바이오마커 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5824303A (en) | 1992-11-13 | 1998-10-20 | Amgen Inc. | Eck receptor ligands |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| CA2352471A1 (en) | 1998-12-22 | 2000-06-29 | Raven Biotechnologies, Inc. | Compositions and methods for generating monoclonal antibodies representative of a specific cell type |
| ES2357296T3 (es) * | 1999-08-17 | 2011-04-25 | Purdue Research Foundation | Anticuerpos dirigidos contra epha2 como un diagnóstico de cáncer. |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| PT1242060E (pt) | 1999-08-17 | 2006-08-31 | Glaxo Group Ltd | Tratamento da doenca metastatica |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| US6541225B1 (en) | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| FR2838742B1 (fr) | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
| WO2004014292A2 (en) | 2002-05-10 | 2004-02-19 | Purdue Research Foundation | EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF |
| JP4557714B2 (ja) * | 2002-05-10 | 2010-10-06 | メディミューン，エルエルシー | ＥｐｈＡ２モノクローナル抗体およびその使用法 |
| WO2006084226A2 (en) | 2005-02-04 | 2006-08-10 | Raven Biotechnologies, Inc. | Antibodies that bind to epha2 and methods of use thereof |
-
2006
- 2006-02-06 WO PCT/US2006/004057 patent/WO2006084226A2/en not_active Ceased
- 2006-02-06 BR BRPI0607450-2A patent/BRPI0607450A2/pt not_active Application Discontinuation
- 2006-02-06 JP JP2007554287A patent/JP5342145B2/ja not_active Expired - Fee Related
- 2006-02-06 RU RU2007133108/13A patent/RU2007133108A/ru not_active Application Discontinuation
- 2006-02-06 CA CA2597198A patent/CA2597198C/en not_active Expired - Fee Related
- 2006-02-06 AT AT06734397T patent/ATE551367T1/de active
- 2006-02-06 AU AU2006210460A patent/AU2006210460B2/en not_active Ceased
- 2006-02-06 KR KR1020077019628A patent/KR101363252B1/ko not_active Expired - Fee Related
- 2006-02-06 CN CN201410213409.1A patent/CN104059150B/zh not_active Expired - Fee Related
- 2006-02-06 US US11/349,327 patent/US7569672B2/en not_active Expired - Fee Related
- 2006-02-06 CN CN200680011089.5A patent/CN101155830B/zh not_active Expired - Fee Related
- 2006-02-06 EP EP06734397A patent/EP1846450B1/en not_active Not-in-force
- 2006-02-06 MX MX2007009403A patent/MX2007009403A/es active IP Right Grant
- 2006-02-06 ZA ZA200707275A patent/ZA200707275B/xx unknown
-
2007
- 2007-07-24 IL IL184803A patent/IL184803A/en not_active IP Right Cessation
- 2007-08-22 CR CR9332A patent/CR9332A/es not_active Application Discontinuation
- 2007-09-03 NO NO20074474A patent/NO20074474L/no not_active Application Discontinuation
-
2009
- 2009-06-30 US US12/495,218 patent/US7776328B2/en not_active Expired - Fee Related
- 2009-11-30 US US12/627,335 patent/US8183357B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008529497A5 (enExample) | ||
| RU2007133108A (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| JP2021184721A5 (enExample) | ||
| JP2019146572A5 (enExample) | ||
| JP2019107018A5 (enExample) | ||
| JP2022191301A5 (enExample) | ||
| JP2024059609A5 (enExample) | ||
| JP2014509835A5 (enExample) | ||
| JP2020019787A5 (enExample) | ||
| RU2012137515A (ru) | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения | |
| JP2017522861A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| JP2006507013A5 (enExample) | ||
| JP2010533498A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| JP2005538701A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| JP2020534830A5 (enExample) | ||
| JP2009297037A5 (enExample) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2010526028A5 (enExample) | ||
| JP2012525854A5 (enExample) | ||
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| JP2014524902A5 (enExample) | ||
| JP2011207882A5 (enExample) |